In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance.
Caspofungin inhibits the synthesis of 1,3-beta-D-glucan, a key step in fungal cell wall biosynthesis. Here we report on its potent in vitro activity (MIC at which 90% of the isolates tested are inhibited = 1 microg per ml of RPMI medium) against 32 Candida albicans fluconazole-susceptible and -resistant clinical isolates irrespective of the underlying resistance mechanism (alterations in ERG11 and/or upregulation of MDR and CDR genes encoding efflux pumps) and provide further evidence that caspofungin is not a substrate for multidrug transporters.
Bachmann
Stefano P
SP
Department of Medicine, Division of Infectious Diseases, University of Texas Health Science Center at San Antonio, South Texas Centers for Biology in Medicine, San Antonio, Texas 78245, USA.
Patterson
Thomas F
TF
López-Ribot
José L
JL
D017088:AIDS-Related Opportunistic Infections / Q000382:microbiology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D001393:Azoles / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects*; D002180:Candidiasis, Oral / Q000382:microbiology; D000077336:Caspofungin; D025141:Drug Resistance, Fungal / Q000235:genetics; D054714:Echinocandins; D015725:Fluconazole / Q000494:pharmacology; D005656:Fungal Proteins / Q000235:genetics; D006801:Humans; D055666:Lipopeptides; D008826:Microbial Sensitivity Tests; D010455:Peptides; D010456:Peptides, Cyclic
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D001393:Azoles; D054714:Echinocandins; D005656:Fungal Proteins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D015725:Fluconazole; D000077336:Caspofungin